0.81
price down icon4.71%   -0.04
after-market 시간 외 거래: .80 -0.01 -1.23%
loading
전일 마감가:
$0.85
열려 있는:
$0.82
하루 거래량:
15,475
Relative Volume:
0.13
시가총액:
$7.11M
수익:
$34.07M
순이익/손실:
$-20.13M
주가수익비율:
-0.0627
EPS:
-12.92
순현금흐름:
$-24.90M
1주 성능:
+1.12%
1개월 성능:
-5.81%
6개월 성능:
-14.08%
1년 성능:
-52.07%
1일 변동 폭
Value
$0.798
$0.85
1주일 범위
Value
$0.7948
$0.87
52주 변동 폭
Value
$0.6513
$2.22

Biofrontera Inc Stock (BFRI) Company Profile

Name
명칭
Biofrontera Inc
Name
전화
781-245-1325
Name
주소
120 PRESIDENTIAL WAY,, WOBURN
Name
직원
93
Name
트위터
Name
다음 수익 날짜
2024-11-13
Name
최신 SEC 제출 서류
Name
BFRI's Discussions on Twitter

BFRI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
BFRI
Biofrontera Inc
0.81 7.11M 34.07M -20.13M -24.90M -12.92
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
146.85 67.28B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.19 45.61B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.93 45.01B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.31 15.25B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
284.25 12.77B 2.76B 1.11B 898.10M 22.77

Biofrontera Inc 주식(BFRI)의 최신 뉴스

pulisher
Apr 16, 2025

Biofrontera Inc. (NASDAQ:BFRI) Sees Large Decrease in Short Interest - Defense World

Apr 16, 2025
pulisher
Apr 13, 2025

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Revista ADVFN

Apr 13, 2025
pulisher
Apr 07, 2025

Biofrontera Inc. Reports Record Sales and Strategic Advances - MSN

Apr 07, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Invests $48,000 in Biofrontera Inc. (NASDAQ:BFRI) - The AM Reporter

Apr 01, 2025
pulisher
Mar 25, 2025

Benchmark maintains Buy rating on Biofrontera stock, target at $7 By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Biofrontera Inc. (NASDAQ:BFRI) Q4 2024 Earnings Call Transcript - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Benchmark maintains Buy rating on Biofrontera stock, target at $7 - Investing.com India

Mar 25, 2025
pulisher
Mar 22, 2025

Biofrontera outlines 2025 growth strategies with new FDA approvals and clinical progress - MSN

Mar 22, 2025
pulisher
Mar 22, 2025

Biofrontera Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Mar 22, 2025
pulisher
Mar 22, 2025

Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada

Mar 22, 2025
pulisher
Mar 22, 2025

Biofrontera Inc. Q4 2024 Earnings: A Deep Dive into the Numbers - AInvest

Mar 22, 2025
pulisher
Mar 21, 2025

Biofrontera Inc. Reports Record Revenue Growth in 2024 - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Biofrontera Inc. reports Q4 EPS (19c) vs $1.65 last year - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Earnings call transcript: Biofrontera Q4 2024 sees revenue growth and strategic shifts - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - GlobeNewswire Inc.

Mar 21, 2025
pulisher
Mar 21, 2025

Earnings Scheduled For March 21, 2025 - Benzinga

Mar 21, 2025
pulisher
Mar 20, 2025

Biofrontera Inc. (BFRI) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Biofrontera Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 18, 2025

Biofrontera Completes Patient Enrollment for Phase 3 Trial of Ameluz in Actinic Keratoses - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Biofrontera completes patient enrollment in Phase 3 study of Ameluz - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Biofrontera Inc. Announces Completion of Patient Enrollment - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Major Milestone: Biofrontera's Skin Cancer Treatment Targets New Body Areas in Phase 3 Trial - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

3 Reasons to Avoid KIND and 1 Stock to Buy Instead - The Globe and Mail

Mar 18, 2025
pulisher
Mar 18, 2025

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk - GlobeNewswire

Mar 18, 2025
pulisher
Mar 14, 2025

Biofrontera (BFRI) to Release Earnings on Friday - Defense World

Mar 14, 2025
pulisher
Mar 11, 2025

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

BIOFRONTERA Earnings Preview: Recent $BFRI Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Dermatology Leader Biofrontera Sets Q4 Earnings Date: Key Growth Updates Expected - StockTitan

Mar 11, 2025
pulisher
Mar 06, 2025

Biofrontera (BFRI) Projected to Post Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 25.0% in February - Defense World

Mar 03, 2025
pulisher
Feb 27, 2025

Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues - Simply Wall St

Feb 27, 2025
pulisher
Feb 22, 2025

When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Yahoo Finance

Feb 22, 2025
pulisher
Feb 22, 2025

Biofrontera (NASDAQ:BFRI) Trading Down 3.5% – What’s Next? - Defense World

Feb 22, 2025
pulisher
Feb 12, 2025

Constellation Brands: A Fallen Star or a Hidden Value Play? - The Globe and Mail

Feb 12, 2025
pulisher
Feb 03, 2025

Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World

Feb 03, 2025
pulisher
Feb 02, 2025

Biofrontera (NASDAQ:BFRI) vs. Sage Therapeutics (NASDAQ:SAGE) Critical Contrast - Defense World

Feb 02, 2025
pulisher
Jan 28, 2025

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 27, 2025

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 26, 2025

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 24, 2025

Bibi go up tomorrow - AInvest

Jan 24, 2025
pulisher
Jan 24, 2025

Biofrontera Inc. Announces Preliminary Third Quarter Revenues - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 08, 2025

Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study - TipRanks

Jan 08, 2025
pulisher
Jan 08, 2025

Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire

Jan 08, 2025
pulisher
Jan 08, 2025

Biofrontera's Ameluz-PDT Skin Cancer Treatment Hits All Phase 3 Endpoints with Strong Results - StockTitan

Jan 08, 2025
pulisher
Jan 06, 2025

Photonics IP Update: December 2024 - Laser Focus World

Jan 06, 2025
pulisher
Dec 23, 2024

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - The Manila Times

Dec 23, 2024
pulisher
Dec 23, 2024

Biofrontera Hits Major Milestone: 100th RhodoLED® XL Lamp Installed as PDT Treatment Demand Surges - StockTitan

Dec 23, 2024
pulisher
Dec 18, 2024

Opendoor Technologies Inc (OPEN-Q) QuotePress Release - The Globe and Mail

Dec 18, 2024
pulisher
Dec 14, 2024

Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World

Dec 14, 2024

Biofrontera Inc (BFRI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$8.48
price up icon 0.47%
$27.00
price up icon 0.00%
$100.62
price down icon 0.69%
$7.57
price up icon 0.13%
$100.68
price down icon 0.69%
$284.25
price down icon 0.17%
자본화:     |  볼륨(24시간):